Differences in chamber structure contribute to the incidence of venous air trap chamber coagulation during AN69ST-CHF: clinical and in vitro evaluation

Table 3 Background patients of unachieved procedures

	ACH-Σ group (3 patients/6 procedures)	Prismaflex group (4 patients/5 procedures)	p value
Age	60 (39, 77)	63 (30, 74.5)	0.70
Male/female	2/1	3/1	0.88
Sepsis% (patients)	33% (1)	40% (2)	0.39
APACHE II score	23 (10, 23.5)	19 (10, 25.5)	0.85
DIC score	4 (2.5, 6.3)	3 (1, 3.5)	0.16
White blood cell (10³/ul)	8.8 (5.5, 19.1)	15 (14.2, 20.7)	0.17
CRP (mg/dl)	10.7 (5.9, 19.0)	4.9 (1.2, 16.7)	0.52
PCT (ng/ml)	1.3 (1.0, 4.0)	0.52 (0.3, 8.8)	0.41
blood platelet (10⁴/ul)	5.6 (3.6, 12.4)	21.8 (11.8, 32.4)	0.03
PT (s)	13.9 (12.7, 14.5)	13.2 (12.7, 16.4)	1.0
APTT (s)	41.3 (37.8, 60.6)	39 (31.1, 51)	0.41
Fibrinogen (mg/dl)	277 (209, 299)	431 (325, 566)	0.04
FDP (ug/ml)	20.9 (11.6, 44.5)	14.7 (9.3, 25.9)	0.41
d-dimer (ug/ml)	18.4 (7.9, 23.6)	14 (7.1, 25.3)	0.93
TAT (ng/ml)	14.8 (3.7, 34.0)	10.2 (7.7, 156)	0.41

Presented data are based on electronic records and include the test results of blood samples drawn at 6:00 a.m. on the morning of the day CHF was performed. Data are expressed as median and interquartile range, and statistical analysis was performed by the Pearson’s chi-square test for gender and also for sepsis, and by the Mann–Whitney U test for the other data
APACHE II score acute physiology and chronic health evaluation II score, DIC score disseminated intravascular coagulation score, CRP c-reactive protein, PCT procalcitonin, PT prothrombin time, APTT activated partial thromboplastin time, FDP fibrin degradation product, TAT thrombin–antithrombin complex

ISSN: 2059-1381